技術指標
指標
數值
方向
MACD(12,26,9)
-0.097
中性
RSI(14)
57.474
中性
STOCH(KDJ)(9,3,3)
38.354
中性
ATR(14)
0.504
低波動
CCI(14)
11.664
中性
Williams %R
62.238
賣出
TRIX(12,20)
0.414
賣出
StochRSI(14)
71.925
買入
搜尋
ImmuCell Corp
ICCC添加自選
11.210USD
+0.150+1.36%
收盤 07-31 16:00（美東）報價延遲15分鐘
101.40M總市值
虧損本益比TTM
關鍵數據
10.980今開
11.350最高
10.15K成交量
虧損本益比TTM
--本益比動
--股利TTM
0.11%換手率
11.060昨收
10.970最低
76.44K成交額
虧損本益比靜
3.75市淨率
0.00%股息率 TTM
-1.22%ROA
10.75052週最高
0.60量比
-2.16M淨利潤
9.05M總股本
-0.0617每股盈餘TTM
0.54Beta
-1.88%ROE
4.52052週最低
3.44%振幅
44.97%毛利率
101.40M總市值
3.26回報/風險
3.05%風險率
TradingKey ImmuCell Corp股票評分
單位: USD 更新時間: 2026-07-31操作建議
ImmuCell Corp當前公司基本面數據相對健康，增長潛力很大。當前估值合理，在藥品行業排名113/155位。機構持股佔比非常高，中期看，股價處於上升通道。近一個月，市場表現較強，基本面評分較高，但較強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
ImmuCell Corp評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
ImmuCell Corp亮點
亮點風險
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
業績高增長
公司營業收入穩步增長，連續3年增長58.22%
業績增長期
公司處於發展階段，最新年度總收入27.64M美元
估值低估
公司最新PE估值-181.69，處於3年歷史低位
機構加倉
最新機構持股2.16M股，環比增加9.59%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉，最新持倉0.00股
分析師目標
基於
0
分析師
--
評級
--
目標均價
--
漲幅空間
ImmuCell Corp新聞
即將為您帶來更多新聞，敬請期待。 。 。
技術指標
移動平均線
指標
數值
方向
MA5
11.130
買入
MA10
11.108
買入
MA20
11.012
買入
MA50
10.344
買入
MA100
8.912
買入
MA200
7.488
買入
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
ImmuCell Corp簡介
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
公司代碼ICCC
公司ImmuCell Corp
CEOte Boekhorst (Olivier)
網址https://immucell.com/
公司股東
相關品種
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%熱門品種
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
常見問題
ImmuCell Corp(ICCC)的當前股價是多少？
ImmuCell Corp(ICCC)的當前股價是 11.21。
ImmuCell Corp 的股票代碼是什麼？
ImmuCell Corp的股票代碼是ICCC。
ImmuCell Corp股票的52週最高點是多少？
ImmuCell Corp股票的52週最高點是10.75。
ImmuCell Corp股票的52週最低點是多少？
ImmuCell Corp股票的52週最低點是4.52。
ImmuCell Corp的市值是多少？
ImmuCell Corp的市值是101.40M。
ImmuCell Corp(ICCC)股票的每股收益（EPS TTM）是多少
ImmuCell Corp(ICCC)股票的每股收益（EPS TTM）是-0.12。